Moderna is preparing to test Health Secretary Robert F. Kennedy Jr.'s tougher vaccine policies with a combination flu-COVID shot. The question is whether it gets approved for both viruses. Why it ...
Moderna’s shares rallied after the biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial. In early trading, the shares were 4.3% higher at $28.34, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results